Clinical Trials

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

67 enrolled

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

795 enrolled

Multiple Myeloma

NCT05730036 2026-03-06

LINKER-MM3

410 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Multiple Myeloma, Recurrence

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT06232707 2024-05-31

ALUMMINATE

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

NCT02856438 2023-12-19

Early Patient Access Treatment Use Protocol CA204-220

No longer available

Multiple Myeloma

NCT02368301 2023-11-30

Expanded Access Treatment Protocol CA204-143

No longer available

Other hematologic neoplasmPlasma cell

Multiple Myeloma

NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

42 enrolled

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

NCT02726581 2023-03-27

CheckMate 602

Phase 3 Completed

170 enrolled 16 charts

Phase 3 Active not recruiting

Multiple Myeloma

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT02654132 2022-11-01

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

117 enrolled 14 charts

Multiple Myeloma

NCT01335399 2022-09-30

ELOQUENT - 1

Phase 3 Completed

748 enrolled 15 charts

Multiple Myeloma

NCT02272803 2022-06-22

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

82 enrolled 13 charts

Multiple Myeloma

NCT01239797 2022-06-01

ELOQUENT - 2

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03104270 2022-03-31

Combination Study for High Risk Multiple Myeloma Patients

Phase 2 Terminated

13 enrolled

Multiple Myeloma

NCT03126617 2021-11-29

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

No longer available

Multiple Myeloma

NCT02612779 2021-07-02

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

74 enrolled 14 charts

Multiple Myeloma

NCT02159365 2019-07-16

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

84 enrolled 11 charts

Multiple Myeloma

NCT01478048 2018-05-21

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

185 enrolled 19 charts

Multiple Myeloma

NCT01241292 2018-02-15

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

7 enrolled 14 charts

Multiple Myeloma

NCT01441973 2018-01-23

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

41 enrolled 17 charts

Smoldering Multiple Myeloma

NCT00742560 2018-01-10

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Other hematologic neoplasmPlasma cell

101 enrolled 20 charts

Multiple Myeloma, Hematologic Neoplasms

NCT02252263 2017-11-01

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

44 enrolled

Multiple Myeloma

NCT01393964 2017-08-03

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

35 enrolled 18 charts

Multiple Myeloma

NCT00726869 2012-08-23

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Phase 1 Terminated

28 enrolled

Multiple Myeloma

NCT00425347 2009-09-23

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

35 enrolled